Search

Displaying results 2651 - 2660 of 2960 in total
  1. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]

    Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML
  2. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued

  3. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

  4. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    [A232955, A232960] In September 2023, the FDA also approved cipaglucosidase alfa for similar indications.[L49241]

  5. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  6. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  7. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

  8. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]

  9. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram.

  10. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    Food and Drug Administration (FDA) approval and is not available in retail pharmacies.